Determining the Optimal Dose of Tenecteplase Before Endovascular Therapy for Ischaemic Stroke (EXTEND-IA TNK Part 2)
EXTEND-IA TNK: Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial Using Intravenous Tenecteplase Part 2
Sponsor: Neuroscience Trials Australia
Listed as NCT03340493, this PHASE2 trial focuses on Ischemic Stroke and remains completed. Sponsored by Neuroscience Trials Australia, it has been updated 9 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2019 — Apr 2020 [monthly]
Active Not Recruiting PHASE2
▶ Show 4 earlier versions
-
Aug 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Apr 2019 — Aug 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Apr 2019 [monthly]
Recruiting PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Neuroscience Trials Australia
- The Florey Institute of Neuroscience and Mental Health
For direct contact, visit the study record on ClinicalTrials.gov .